9/13/2026

Janusmed sex and gender

Janusmed sex and gender – Ursodeoxycholic acid

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Ursodeoxycholic acid

Ursodeoxycholic acid

Class : A

Show all info

Print

Contact us

  1. Song P, Zhang X, Feng W, et al. Biological synthesis of ursodeoxycholic acid. Front Microbiol. 2023;14:1140662.

  2. Ursofalk (ursodeoxicholsyra). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2024-11-29, cited 2026-06-25]

  3. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - Urso 250 (ursodeoxycholic acid). Drugs@FDA [www]. [updated 1997-12-10, cited 2026-06-25].

  4. Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology. 2013;144(3):560-569 e7; quiz e13-4.

  5. Yamamoto R, Tazuma S, Kanno K, et al. Ursodeoxycholic acid after bile duct stone removal and risk factors for recurrence: a randomized trial. J Hepatobiliary Pancreat Sci. 2016;23(2):132-6.

  6. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]

  1. Song P, Zhang X, Feng W, et al. Biological synthesis of ursodeoxycholic acid. Front Microbiol. 2023;14:1140662.
  2. Ursofalk (ursodeoxicholsyra). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2024-11-29, cited 2026-06-25]
  3. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - Urso 250 (ursodeoxycholic acid). Drugs@FDA [www]. [updated 1997-12-10, cited 2026-06-25].
  4. Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology. 2013;144(3):560-569 e7; quiz e13-4.
  5. Yamamoto R, Tazuma S, Kanno K, et al. Ursodeoxycholic acid after bile duct stone removal and risk factors for recurrence: a randomized trial. J Hepatobiliary Pancreat Sci. 2016;23(2):132-6.
  6. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]